# PTCT catalysts: PTC THERAPEUTICS, INC. PDUFA dates and FDA events

Canonical: https://sec-api.dev/companies/ptct/catalysts

> PTC THERAPEUTICS, INC. (PTCT) has 6 upcoming catalysts. The next is the PTC844 topline data readout, Sep to Dec 2027.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: month only, exact day, quarter only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Company

| Field | Value |
| --- | --- |
| Name | PTC THERAPEUTICS, INC. |
| Ticker | PTCT (Nasdaq) |
| SEC CIK | 1070081 |
| SIC | 2834 |
| SEC filings | https://sec-api.dev/companies/ptct |

## Cash runway

Cash $2.13B as of 2026-09-30; quarterly burn $25.3M; about 252.2 months of runway at that rate (XBRL company facts, accession 0001104659-26-120223).

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| Jul 2024 | [Translarna™ (ataluren) NDA/BLA submission](https://sec-api.dev/pdufa/ataluren) | PTCT | nmDMD | completed | "Based on feedback from the FDA, we re-submitted the NDA in July 2024, based on the results from Study 041 and from our international drug registry study for nmDMD patients receiving Translarna." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1070081/000110465926017575/tmb-20251231x10k.htm)) |
| Jul 2024 | [Sephience™ (sepiapterin) NDA/BLA submission](https://sec-api.dev/pdufa/sepiapterin) | PTCT | and adult patients with PKU | completed | "In July 2024 the Company submitted an NDA to the FDA for sepiapterin for the treatment of pediatric and adult patients with PKU, including the full spectrum of ages and disease subtypes, in the United States." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1070081/000107008125000019/tmb-20250331x10q.htm)) |
| November 13, 2024 | [Kebilidi (eladocagene exuparvovec) FDA approval](https://sec-api.dev/pdufa/eladocagene-exuparvovec) | PTCT | children and adults with AADC deficiency | completed, approved | "PTC was granted the PRV on November 13, 2024 along with the U.S. Food and Drug Administration (FDA) approval of KEBILIDI™ (eladocagene exuparvovec-tneq) for the treatment of children and adults with AADC deficiency, including the full spectrum of disease severity." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1070081/000107008124000026/tmb-20241126xex99d1.htm)) |
| November 13, 2024 | [PTC THERAPEUTICS, INC. PDUFA date](https://sec-api.dev/companies/ptct/catalysts) | PTCT |  | scheduled | "The application was granted priority review with a target regulatory action date of November 13, 2024." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1070081/000107008125000012/tmb-20241231x10k.htm)) |
| Dec 2024 | [Vatiquinone NDA/BLA submission](https://sec-api.dev/pdufa/vatiquinone) | PTCT | children and adults living with FA | completed | "In December 2024, the Company submitted an NDA to the FDA for vatiquinone for the treatment of children and adults living with FA." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1070081/000110465926120223/tmb-20260930x10q.htm)) |
| December 31, 2024 | [Kebilidi (eladocagene exuparvovec) FDA approval](https://sec-api.dev/pdufa/eladocagene-exuparvovec) | PTCT |  | completed, approved | "For the year ended December 31, 2024, in connection with our FDA approval of Kebilidi, we received a Priority Review Voucher, or PRV, and sold the PRV for aggregate net proceeds of $148.0 million." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1070081/000110465926017575/tmb-20251231x10k.htm)) |
| February 27, 2025 | [PTC THERAPEUTICS, INC. earnings report](https://sec-api.dev/companies/ptct/catalysts) | PTCT |  | completed | "Reports Fourth Quarter and Full Year 2024 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1070081/000107008125000011/tmb-20250227xex99d1.htm)) |
| May 6, 2025 | [PTC THERAPEUTICS, INC. earnings report](https://sec-api.dev/companies/ptct/catalysts) | PTCT |  | completed | "Reports First Quarter 2025 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1070081/000107008125000018/tmb-20250506xex99d1.htm)) |
| July 28, 2025 | [Sephience™ (sepiapterin) FDA approval](https://sec-api.dev/pdufa/sepiapterin) | PTCT | children and adults living with PKU | completed, approved | "On July 28, 2025, PTC Therapeutics, Inc. (the "Company"), announced that the U.S. Food and Drug Administration ("FDA") approved Sephience™ (sepiapterin) for the treatment of children and adults living with phenylketonuria ("PKU")." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1070081/000155837025009663/tmb-20250728x8k.htm)) |
| July 29, 2025 | [Kebilidi (eladocagene exuparvovec) PDUFA date](https://sec-api.dev/pdufa/eladocagene-exuparvovec) | PTCT | AADC deficiency | scheduled | "o Kebilidi (eladocagene exuparvovec-tneq) gene therapy for the treatment of AADC deficiency in the U.S., approved in November 2024 o Sepiapterin for children and adults with PKU, with a target regulatory action date of July 29, 2025 o Vatiquinone for children and adults with Friedreich's ataxia, granted priority review with a target regulatory action date of August 19, 2025 o Translarna for nmDMD" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1070081/000107008125000011/tmb-20250227xex99d1.htm)) |
| July 29, 2025 | [Sephience™ (sepiapterin) PDUFA date](https://sec-api.dev/pdufa/sepiapterin) | PTCT |  | completed, approved | "- Positive CHMP opinion for Sephience™ (sepiapterin) received in April 2025, NDA review remains on track for July 29, 2025 PDUFA date -" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1070081/000107008125000018/tmb-20250506xex99d1.htm)) |
| August 7, 2025 | [PTC THERAPEUTICS, INC. earnings report](https://sec-api.dev/companies/ptct/catalysts) | PTCT |  | completed | "PTC Therapeutics Provides Corporate Update and Reports Second Quarter 2025 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1070081/000155837025010770/tmb-20250807xex99d1.htm)) |
| August 18, 2025 | [Nda220049 complete response letter (CRL)](https://sec-api.dev/pdufa/nda220049) | PTCT |  | completed, complete response letter | "We have completed our review of this application, as amended, and have determined that we cannot approve this application in its present form." ([FDA complete response letter database](https://api.fda.gov/transparency/crl.json?search=file_name:%22CRL_NDA220049_20250818.pdf%22)) |
| August 19, 2025 | [PTC THERAPEUTICS, INC. PDUFA date](https://sec-api.dev/companies/ptct/catalysts) | PTCT |  | scheduled | "NDA reviews for vatiquinone (Friedreich's ataxia) and Translarna (nonsense mutation DMD) are ongoing, with regulatory action date of August 19, 2025 for vatiquinone" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1070081/000155837025010770/tmb-20250807xex99d1.htm)) |
| August 19, 2025 | [Vatiquinone complete response letter (CRL)](https://sec-api.dev/pdufa/vatiquinone) | PTCT | children and adults living with Friedreich's ataxia | completed, complete response letter | "WARREN, N.J., August 19, 2025 -- PTC Therapeutics, Inc. (NASDAQ: PTCT) announced today that the U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) related to the New Drug Application (NDA) for vatiquinone for the treatment of children and adults living with Friedreich's ataxia." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1070081/000155837025011658/tmb-20250819xex99d1.htm)) |
| August 19, 2025 | [Vatiquinone PDUFA date](https://sec-api.dev/pdufa/vatiquinone) | PTCT |  | completed, complete response letter | "In February 2025, the FDA accepted for filing the NDA and granted priority review with a target regulatory action date of August 19, 2025." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1070081/000155837025010796/tmb-20250630x10q.htm)) |
| November 4, 2025 | [PTC THERAPEUTICS, INC. earnings report](https://sec-api.dev/companies/ptct/catalysts) | PTCT |  | completed | "PTC Therapeutics Provides Corporate Update and Reports Third Quarter 2025 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1070081/000107008125000026/tmb-20251104xex99d1.htm)) |
| February 10, 2026 | [Translarna™ (ataluren) primary completion](https://sec-api.dev/pdufa/ataluren) | PTCT | Duchenne Muscular Dystrophy | withdrawn | "NCT01247207 (Study of Ataluren in Previously Treated Participants With Nonsense Mutation Dystrophinopathy (nmDBMD)): Overall Status TERMINATED; Phase PHASE3; Primary Completion 2026-02-10 (ACTUAL); Lead Sponsor PTC Therapeutics; Results First Posted 2026-10-08." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT01247207)) |
| February 19, 2026 | [PTC THERAPEUTICS, INC. earnings report](https://sec-api.dev/companies/ptct/catalysts) | PTCT |  | completed | "Reports Fourth Quarter and Full Year 2025 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1070081/000110465926017546/tmb-20260219xex99d1.htm)) |
| April 28, 2026 | [Votoplam topline data readout](https://sec-api.dev/pdufa/votoplam) | PTCT |  | completed, positive | "On April 28, 2026, PTC Therapeutics, Inc. (the "Company") reported positive topline results from the 24-month interim analysis of the PIVOT-HD long-term extension study of votoplam." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1070081/000107008126000006/tmb-20260428x8k.htm)) |
| May 7, 2026 | [PTC THERAPEUTICS, INC. earnings report](https://sec-api.dev/companies/ptct/catalysts) | PTCT |  | completed | "PTC Therapeutics Provides Corporate Update and Reports First Quarter 2026 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1070081/000107008126000011/tmb-20260507xex99d1.htm)) |
| June 30, 2026 | [PTC612 trial start](https://sec-api.dev/pdufa/ptc612) | PTCT |  | completed | "During the quarter ended June 30, 2026, the Company initiated a Phase 1 study of PTC612, its oral NLRP3 inhibitor, and completed several of the single and multiple ascending dose treatment cohorts." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1070081/000107008126000017/tmb-20260630x10q.htm)) |
| Q3 2026 | [PTC844 trial start](https://sec-api.dev/pdufa/ptc844) | PTCT |  | scheduled | "The Company expects to initiate a Phase 2a study of PTC844, its next-generation DHODH inhibitor, in the third quarter of 2026." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1070081/000107008126000017/tmb-20260630x10q.htm)) |
| July 21, 2026 | [Sephience™ (sepiapterin) primary completion](https://sec-api.dev/pdufa/sepiapterin) | PTCT | Phenylketonuria | completed | "NCT05166161 (A Long-Term Safety Study of PTC923 in Participants With Phenylketonuria): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2026-07-21 (ACTUAL); Lead Sponsor PTC Therapeutics." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05166161)) |
| July 28, 2026 | [PTC THERAPEUTICS, INC. earnings report](https://sec-api.dev/companies/ptct/catalysts) | PTCT |  | completed | "PTC Therapeutics Provides Corporate Update and Reports Second Quarter 2026 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1070081/000107008126000016/tmb-20260728xex99d1.htm)) |
| Q4 2026 | [Isaralgagene civaparvovec NDA/BLA submission](https://sec-api.dev/pdufa/isaralgagene-civaparvovec) | PTCT |  | scheduled | "- Acquired ST-920 Fabry disease gene therapy; BLA submission expected to be completed in Q4 2026 -" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1070081/000110465926120200/tmb-ex99d1.htm)) |
| October 29, 2026 | [PTC THERAPEUTICS, INC. earnings report](https://sec-api.dev/companies/ptct/catalysts) | PTCT |  | completed | "PTC Therapeutics Provides Corporate Update and Reports Third Quarter 2026 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1070081/000110465926120200/tmb-ex99d1.htm)) |
| Sep to Dec 2027 | [PTC844 topline data readout](https://sec-api.dev/pdufa/ptc844) | PTCT | Rheumatoid Arthritis | scheduled | "NCT07779616 (Study of PTC844 in Participants With Active Rheumatoid Arthritis): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-09-30 (ESTIMATED); Lead Sponsor PTC Therapeutics." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07779616)) |
| September 2027 | [PTC844 primary completion](https://sec-api.dev/pdufa/ptc844) | PTCT | Rheumatoid Arthritis | scheduled | "NCT07779616 (Study of PTC844 in Participants With Active Rheumatoid Arthritis): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-09-30 (ESTIMATED); Lead Sponsor PTC Therapeutics." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07779616)) |
| Dec 2027 to Mar 2028 | [Vatiquinone topline data readout](https://sec-api.dev/pdufa/vatiquinone) | PTCT | Friedreich Ataxia | scheduled | "NCT05515536 (A Study to Assess the Safety and Efficacy of Vatiquinone in Participants With Friedreich Ataxia): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-12-31 (ESTIMATED); Lead Sponsor PTC Therapeutics." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05515536)) |
| December 2027 | [Vatiquinone primary completion](https://sec-api.dev/pdufa/vatiquinone) | PTCT | Friedreich Ataxia | scheduled | "NCT05515536 (A Study to Assess the Safety and Efficacy of Vatiquinone in Participants With Friedreich Ataxia): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-12-31 (ESTIMATED); Lead Sponsor PTC Therapeutics." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05515536)) |
| Mar to Jun 2029 | [Vatiquinone topline data readout](https://sec-api.dev/pdufa/vatiquinone) | PTCT | Friedreich's Ataxia | scheduled | "NCT07681713 (Long-Term Efficacy Study of Vatiquinone for the Treatment of Friedreich's Ataxia (FA)): Overall Status NOT_YET_RECRUITING; Phase PHASE3; Primary Completion 2029-03-15 (ESTIMATED); Lead Sponsor PTC Therapeutics." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07681713)) |
| March 2029 | [Vatiquinone primary completion](https://sec-api.dev/pdufa/vatiquinone) | PTCT | Friedreich's Ataxia | scheduled | "NCT07681713 (Long-Term Efficacy Study of Vatiquinone for the Treatment of Friedreich's Ataxia (FA)): Overall Status NOT_YET_RECRUITING; Phase PHASE3; Primary Completion 2029-03-15 (ESTIMATED); Lead Sponsor PTC Therapeutics." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07681713)) |

## Drugs

- [Translarna™ (ataluren)](https://sec-api.dev/pdufa/ataluren): nmdmd, Duchenne Muscular Dystrophy
- [Kebilidi (eladocagene exuparvovec)](https://sec-api.dev/pdufa/eladocagene-exuparvovec): aadc deficiency, children and adults with aadc deficiency
- [Isaralgagene civaparvovec](https://sec-api.dev/pdufa/isaralgagene-civaparvovec): with fabry disease
- [Nda220049](https://sec-api.dev/pdufa/nda220049): 
- [PTC612](https://sec-api.dev/pdufa/ptc612): 
- [PTC844](https://sec-api.dev/pdufa/ptc844): Rheumatoid Arthritis
- [Sephience™ (sepiapterin)](https://sec-api.dev/pdufa/sepiapterin): and adult patients with pku, children and adults living with pku, children and adults living with phenylketonuria, children and adults, Phenylketonuria
- [Vatiquinone](https://sec-api.dev/pdufa/vatiquinone): children and adults living with fa, children and adults living with friedreich's ataxia, Friedreich Ataxia, Friedreich's Ataxia

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/companies/ptct/catalysts.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "PTCT catalysts: PTC THERAPEUTICS, INC. PDUFA dates and FDA events." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/companies/ptct/catalysts

```bibtex
@misc{secapidev_companies_ptct_catalysts_20261116,
  title        = {PTCT catalysts: PTC THERAPEUTICS, INC. PDUFA dates and FDA events},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/companies/ptct/catalysts}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_companies_ptct_catalysts_20261116","title":"PTCT catalysts: PTC THERAPEUTICS, INC. PDUFA dates and FDA events","publisher":"sec-api.dev","URL":"https://sec-api.dev/companies/ptct/catalysts","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
